Babylon raised $600 million on an initial vision that evolved significantly over time [#393]. The company succeeded in proving remote medicine was viable and inspired enormous downstream innovation—20+ ex-Babylonians founded subsequent ventures, and nearly every digital health company now has someone from the Babylon network in leadership [#393].
But the company itself became a casualty of timing and investor confidence rather than product failure. It raised into a post-COVID correction when appetite for digital health was already contracting [#393], and its collapse became a reference point that damaged confidence in the entire sector, making fundraising harder for competitors [#319].
The lesson for founders isn't about product. It's about the gap between what you raise money to build and what circumstances allow you to deliver. Babylon proved the capability—remote diagnosis, triage, medicine delivery on a phone worked [#393]. The company's value to healthtech came from showing what's possible, not from commercial execution [#350]. Founders should recognise that venture success and sector impact are sometimes disconnected. Babylon failed commercially but succeeded in changing what the industry believed it could do.
Search 450+ episodes and 42,000 chunks of healthtech conversation.